You can buy or sell Immuron and other stocks, options, ETFs, and crypto commission-free!
Immuron Ltd. engages in the research and development of oral immunotherapy treatments using dairy-derived antibody products for humans. It operates through the following segments: Research and Development; HyperImmune Products; and Corporate. Read More The Research and Development segment involves the R&D projects performed in Australia and Israel. The HyperImmune Products segment comprises of Travelan activities which occur in Australia, New Zealand, Canada, and the United States. The Corporate segment covers company activities. The company was founded on January 13, 1994 and is headquartered in Southbank, Australia.
Carlton, Victoria (VIC)
52 Week High
52 Week Low
Research And Development